Skip to content

Home

Karma is an LA based biotech company dedicated to solving the cost, scaling and duration issues associated with ex vivo gene and cell therapies.

  • Karma spent five years developing its proprietary, IP protected tech as the basis of our own pipeline of in vivo immunotherapies, with a focus on neuroinflammatory and autoimmune indications via our Xavine tolerogenic vaccine platform.
  • Karma’s unique LNP-based technology can convert immune cells in vivo into biofactories that make and secrete therapeutic or immune-system effecting proteins at the site of disease.
  • Karma anticipates manufacturing GMP-grade product within 12 months and carrying out first-in-human clinical trials by 2025.

SNIPR: KARMA’S PROPRIETARY LIPID NANOPARTICLE PLATFORM

SNIPR stands for Sub-Nanoparticle Intracellular Payload Release

SAFE

Low toxicity in vitro and in vivo

FLEXIBLE

Can deliver multiple payloads at once

STABLE

Unique process keeps SNIPR stable for weeks at 4oC

SCALABLE

Proprietary robotic manufacturing process

SNIPR PAYLOADS 

Their unique 3D structure allows loading of different payloads in controlled ratios

BIOLOGIC DRUGS ENGINEERED IN VIVO 

Karma’s unique approach to biotherapeutics enables better outcomes for vast patient populations

KARMA HAS ALREADY ENGINEERED IMMUNE CELLS IN VIVO 

We engineer immune cells in vivo to produce bioavailable proteins

Robust DNA & RNA delivery to immune cells


Edits genes in human immune cells


Targeted to immune cells in vivo


Engineers cells to secrete therapeutic or immune-relevant proteins


Secreted therapeutic proteins act in local tissues or on local cells

OUR TEAM

Karma is primed for success with a great mix of geeks and company builders

Andrew Gray, PhD

  • PhD in Immune tolerance induced by cancer
  • IndieBio alum
  • Directs Karma’s synthetic bio strategy

Alan Johnson, MBA, BS

  • Synthetic chemist with 20+ years experience
  • Iterates and validates Karma’s novel LNPs

Don Johnson, PhD

  • PhD in Biomedical Materials Science
  • NIH and IndieBio alum
  • Guides Karma’s LNP design strategy

Joe Turner

  • Previously Managing Director at Blackstone/PJT
  • MS Finance NYU
  • Leads Karma’s finance and business strategy, including commercial partnerships

Luciana C. Veiras, PhD

  • Immunophysiologist

Xazmin Custer, PhD

  • Metabolism & cell signaling expert

Mariana Uchoa, PhD

  • XavineTM research & development lead

ADVISORY BOARD

Karma has exceptional VC backers and is actively building an expert SAB

Todd Peterson, PhD

Former CSO of Allen Institute & former CTO of Viridos

James Treanor, PhD

Founding CEO, ADRx & 18 years at AMGEN

W. Martin Kast, PhD

Immune regulation guru

Paul Feldstein, PhD

Cell-specific expression expert

Andy Alexander, PhD DVM, DABT, MBA

FDA whisperer

Mike Siani-Rose

Project management and biopharma manufacturing pro

INVESTORS

CAREERS

Interested in joining the team at Karma?
Here are our current openings:

CONTACT US

Karma Biotechnologies

LOCATION

370 Amapola Avenue, Suite 101
Torrance, CA 90501

FOLLOW US ON SOCIAL MEDIA

LinkedIn
www.linkedin.com/company/karma-biotechnologies

Twitter
www.twitter.com/karmabiotech

Instagram
www.instagram.com/karmabiotech